SynthesisAnnals of the rheumatic diseases2006
Long term safety of etanercept in elderly subjects with rheumatic diseases.
Synthesis in Annals of the rheumatic diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 142 citations in OpenAlex.
- Frailty in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: Current evidence and knowledge gaps.Therapeutic advances in musculoskeletal disease · 2026Review
- Retention Rates of Biological Drugs in Spondyloarthritis: A 24-Month Observational Study in Patients Aged 60 Years or Older.Drugs - real world outcomes · 2025Article
- Biological treatment in elderly and young patients with ankylosing spondylitis: TURKBIO real-life data results.Archives of rheumatology · 2024Article
- Therapy of PsO in Special Subsets of Patients.Biomedicines · 2022Review
- Effectiveness and drug retention of biologic disease modifying antirheumatic drugs in Korean patients with late onset ankylosing spondylitis.Scientific reports · 2021Article
- Safety and Effectiveness of Biologic Disease-Modifying Antirheumatic Drugs in Older Patients with Rheumatoid Arthritis: A Prospective Cohort Study.Drugs & aging · 2020Article
- Does Older Age have an Impact on Rituximab Efficacy and Safety? Results from the NOR-DMARD Register.Drugs & aging · 2020Observational
- A Single Codon Optimization Enhances Recombinant Human TNF-BioMed research international · 2018Article
- Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis.Arthritis research & therapy · 2017Observational
- The TNF-α antagonist etanercept reverses age-related decreases in colonic SERT expression and faecal output in mice.Scientific reports · 2017Article
- Article
- Safety and Efficacy of Biological Disease-Modifying Antirheumatic Drugs in Older Rheumatoid Arthritis Patients: Staying the Distance.Drugs & aging · 2016Review
- Targeting Low Disease Activity in Elderly-Onset Rheumatoid Arthritis: Current and Future Roles of Biological Disease-Modifying Antirheumatic Drugs.Drugs & aging · 2016Review
- Biologics Prescribing for Rheumatoid Arthritis in Older Patients: A Single-Center Retrospective Cross-Sectional Study.Rheumatology and therapy · 2015Article
- Diagnosis and Management of Late-Onset Spondyloarthritis: Implications of Treat-to-Target Recommendations.Drugs & aging · 2015Review
- Sustained intra-articular delivery of IL-1RA from a thermally-responsive elastin-like polypeptide as a therapy for post-traumatic arthritis.European cells & materials · 2015Article
- Review
- Managing moderate-to-severe psoriasis in the elderly.Drugs & aging · 2014Review
- Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis.Biologics : targets & therapy · 2014Review
- Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis.Rheumatology (Oxford, England) · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged > or =65 years in comparison with subjects aged <65 years.
methodsSafety data from an integrated database of 4322 subjects enrolled in 18 RA trials, 2 PsA trials, and 2 AS trials were analysed. Safety end points included subject incidence of all adverse events (AE), serious adverse events (SAE), infectious events (IE), medically important infections (MII), and deaths. Events of particular interest in subjects treated with TNF modulating biological treatments, including demyelinating diseases, tuberculosis, lymphomas, and cardiovascular diseases, were also evaluated.
resultsThe incidence of AE, SAE, IE, MII, and malignancies was not significantly raised in elderly subjects in comparison with subjects aged <65 years. No cases of tuberculosis were reported in the trials. Demyelinating diseases were seen only in subjects aged <65 years. The incidence and types of death in the elderly subjects were consistent with the expected rates for subjects of comparable age.
conclusionsEtanercept is a generally safe and well tolerated biological agent for treatment of rheumatological diseases in the elderly, and the risk of AE in these studies was no greater in subjects aged > or =65 years than in younger subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.